

From: cara lansden/cambridge/biogen;nsf:cara.lansden@biogenidec.com;smtp
Sent: Wed Jun 14 2006 17:49:49 EDT
To: gilmore o'neill/cambridge/biogen@biogenidec; [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED] tammy
sarnelli/cambridge/biogen@biogenidec;
Subject: Fw: BG12 MS IND

To the BG-12 MS CDT:

The BG-12 MS IND is no longer on clinical hold!!! Thank you all for your hard work in turning around the response so quickly.

Regards,
Cara

Cara Lansden
Sr. Manager, Clinical Development
Biogen Idec
Tel +617-679-2658
Fax +617-679-3518
Email: cara.lansden@biogenidec.com

----- Forwarded by Cara Lansden/Cambridge/Biogen on 06/14/2006 06:45 PM -----

Tammy Sarnelli/Cambridge/Biogen
14-Jun-2006 04:23 PM
Message Size: 2.0 KB

To
BG-12 Program Team, Scott Stecher/Cambridge/Biogen@BiogenIdec
cc
[REDACTED]
Subject
BG12 MS IND

Hello everyone:

We were notified today by FDA that the clinical hold has been lifted! We are now free to begin the QTc study.

Thank you to all of you who worked so hard to make the submission quickly.

Sincerely
Tammy